These authors contributed equally to this study.
Proteomic profiling of the autoimmune response to breast cancer antigens uncovers a suppressive effect of hormone therapy
Version of Record online: 10 MAY 2013
© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
PROTEOMICS - Clinical Applications
Special Issue: Focus on Cancer Proteomics
Volume 7, Issue 5-6, pages 327–336, June 2013
How to Cite
Chao, T., Ladd, J. J., Qiu, J., Johnson, M. M., Israel, R., Chin, A., Wang, H., Prentice, R. L., Feng, Z., Disis, M. L. and Hanash, S. (2013), Proteomic profiling of the autoimmune response to breast cancer antigens uncovers a suppressive effect of hormone therapy. Prot. Clin. Appl., 7: 327–336. doi: 10.1002/prca.201200058
Colour Online: See the article online to view Fig. 4 in colour.
- Issue online: 18 JUN 2013
- Version of Record online: 10 MAY 2013
- Accepted manuscript online: 12 FEB 2013 02:41AM EST
- Manuscript Accepted: 3 DEC 2012
- Manuscript Revised: 11 OCT 2012
- Manuscript Received: 21 JUN 2012
As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.
Figure S1. Reproducibility of microarrays was assessed by hybridization of samples on multiple arrays. Pearson correlations between replicate spots for two different samples are a) 0.96 and b) 0.91. Data is displayed as the log-2 transform of fluorescent intensity.
Figure S2. Plots of autoantibody reactivity medians against SKBR3-arrayed proteins from individual cancer samples separated by clinical characteristics: (A) subject age, (B) tumor stage at time of diagnosis and c) time of blood draw prior to diagnosis of breast cancer. Samples are separated by hormone therapy use and further separated based on the median value of the examined clinical characteristic. The median subject age was 65. The median time of blood draw prior to diagnosis was 150 days. * indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001, **** indicates p<0.0001.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.